

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 APRIL 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

<u>Item</u>	<u>PBAC Advice</u>
Abacavir with lamivudine and zidovudine	<p>The sponsor requested the delisting of Trizivir[®] (abacavir with lamivudine and zidovudine) from the Pharmaceutical Benefits Scheme (PBS).</p> <p>The PBAC noted the low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Fosamprenavir	<p>The sponsor requested the delisting of Telzir[®] (fosamprenavir) from the PBS.</p> <p>The PBAC noted the low number of services in the last financial year and that there are suitable alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Paraffin with retinol palmitate	<p>The sponsor requested the delisting of VitA-POS[®] (paraffin with retinol palmitate) from the PBS.</p> <p>The PBAC noted the moderate number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Tropisetron	<p>The sponsor requested the delisting of Tropisetron-AFT[™] (tropisetron) from the PBS.</p> <p>The PBAC noted the low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>

A handwritten signature in black ink, consisting of several stylized, overlapping loops and a long horizontal stroke extending to the right.

Vanessa McMahon
Director, PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
20 March 2024